Compare Abbott Laboratories (ABT) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Abbott Laboratories trades at $110.71 (market cap $187.95B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $60.43. The key difference: Abbott Laboratories pays a 2.32% dividend while Vanguard Emerging Markets Stock Index Fund ETF pays none, and Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | VWO | |
|---|---|---|
Market Cap | $187.95B | — |
Sector | Health | — |
52-Week High | $136.62 | $61.24 |
52-Week Low | $82.57 | $51.20 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
VWO trades at $60.49, up 0.27% with a bullish technical signal from moving averages. The ETF shows strong institutional accumulation with multiple advisors increasing positions recently. Emerging markets are experiencing record capital inflows as investors diversify beyond US stocks, with VWO offering low-cost exposure to developing economies at a 0.06% expense ratio.
The outlook remains positive given institutional support and emerging market momentum, though risks include China's weighting impact and potential volatility. VWO's low expense ratio and 2.4% dividend yield provide competitive advantages over peers like EEM (0.69% fee) for emerging market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
